Slide 1: Craneware plc: Final Results FY26
Craneware plc: Final Results FY26 Keith Neilson, CEO and Co-founder, Craig Preston, CFO © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 1
Slide 2: Agenda
Agenda 01 Introduction & Overview of the Period 02 Cyber Security Incident Update 03 Financial Review 04 340B Market Update & Our Response 05 Growth Strategy: A consistent focus on our strengths 06 Outlook © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by tra
Slide 3: We partner with healthcare providers across the US
We partner with healthcare Financially resilient providers across the US to improve and sustain their $185m ARR, NRR of 100% operational and financial Average relationship of top 10 performance. customers is 21 years c.90% of revenue is recurring Our innovative software Commitment to 30%+ EBITDA sol
Slide 4: FY26 Performance review and outlook
Introduction FY26 Performance review and outlook FY26 impacted by 340B headwinds Solid foundation of recurring revenue Confident in FY28 growth • Further certainty within 340B • Slow down in 340B transaction • Cyber security incident now entered market anticipated through FY27 at revenues in H2 as u
Slide 5: Cyber security incident update
Introduction Cyber security incident update What happened Current status • Incident contained: In July 2026, the Group identified • Moving into Remediation phase: The Group and promptly contained unauthorised access to part continues to assess the scope, notify affected parties of its data environme
Slide 6: A robust sales performance
A robust sales performance Continued expansion sales and competitive wins FY26 - Annual Value of 'new' Sales Example H2 new customer wins: New • 3-year 340B Program modernisation contract with an independent regional health Hospitals, Existing system replacing a competitor. 10% Hospitals • 5-year Re
Slide 7: FY26 Financial Results
FY26 Financial Results Craig Preston, CFO © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 7
Slide 8: FY26 Financial KPIs & FY27 Reset
FY26 Financial KPIs & FY27 Reset $206.0m $67.1m • FY26 revenue performance below our expectations due to 340B (FY25: $205.7m) (FY25: $65.3m) headwinds: underlying sales performance in line with prior year, healthy margin performance and cash conversion. Revenue Adj. EBITDA • Our ARR provides a stron
Slide 9: FY26 Review: Revenue and earnings
Revenue (millions) $250 $200 $150 $100 189.3 205.7 206.0 165.5 174.0 $50 FY26 Review: Revenue and $0 FY22 FY23 FY24 FY25 FY26 earnings Adj. EBITDA (millions) $80 ─ Revenue steady at $206.0m. $60 (FY25: $205.7m) $40 65.3 67.1 54.9 58.3 $20 51.8 ─ Adj EBITDA increased 3% to $67.1m. $0 FY22 FY23 FY24 F
Slide 10: FY26 Review: Cash & Dividend
FY26 Review: Cash & Dividend Cash ($m) • Continued strong cash management 90 FY 2026 FY 2025 80 $000 $000 70 Cash at period end $54.8m Cash generated from operations 55,435 69,595 60 Tax paid (12,541) (9,697) (FY25: $55.9m). Net cash from operations 42,894 59,898 50 40 78.5 Purchase of plant and equ
Slide 11: Annuity SaaS Model
Annuity SaaS Model Driving contracted recurring revenue $m 200 Non-recurring SaaS Software Revenue revenue: $31m, Contracted Recurring 15% of total Typical multi-year underlying contracts ─ High visibility of future revenues. Revenue 150 Other recurring revenue ─ Transactional recurring revenue, wit
Slide 12: Income Statement & EPS
Income Statement & EPS Headline Results Revenue Adj. EBITDA Adj. Basic EPS* →0% 3% 1% Adj. EBITDA Statutory Basic margin PBT EPS 33% 7% 1% (FY25: 32%) R&D Spend Eff Tax Rate EPS FY 2026 FY 2025 $59.6m $16.9m 23% (FY25: $57.3m with Capitalised (FY25: 18%) Basic ($ per share) 0.566 0.562 $14.9
Slide 13: Strong Balance Sheet
FY 2026 FY 2025 $000 $000 ASSETS Non-Current Assets Property, plant and equipment 4,736 6,252 Intangible assets - goodwill 235,236 235,236 Intangible assets - acquired intangibles 103,564 124,485 Intangible assets – other 66,589 61,243 Trade and other receivables 2,582 3,752 Deferred tax - 499 412,7
Slide 14: Capital Allocation
Capital Allocation Balancing the needs of our stakeholders Dividend plus buybacks has seen $98.2m Rapidly paid down debt, while in high- Maintain R&D spend of approx. 25% of (c£75.9m*) returned to shareholders in 5 interest rate environment, gives revenues, as we see considerable years. >$156m of “f
Slide 15: 340B Market, Growth Strategy & Outlook
340 Market, Growth Strategy & Outlook Keith Neilson, CEO © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 15
Slide 16: 340B Market evolution
Market overview 340B Market evolution 340B market is maturing Potential implications for customers What is to come? This $100 billion program is facing increasing Rebate model • Legal challenges to 340B & Rebate. regulatory, operational, and financial • Introduces significant cash flow • Rebate mode
Slide 17: Trisus OneLink Medication
Trisus® OneLink℠ Medication One workflow from eligibility through financial validation Trisus® OneLink℠ Medication One workflow from eligibility through financial validation Trisus® OneLink℠ Medication brings 340B rebates, Maximum Fair Price refunds, and manufacturer and Enhanced Services Platform r
Slide 18: Major increase in embedded Trisus capabilities and return to Best in KLAS
Growth Strategy Major increase in embedded Trisus® capabilities and return to Best in KLAS for Trisus Chargemaster Trisus Assist Trisus Assist for Reimbursement Trisus Labor & Productivity Intelligence AI-powered assistant AI-enhanced demand AI-powered contract streamlines compliance forecasting and
Slide 19: A consistent focus on our strengths
Growth Strategy A consistent focus on our strengths Leverage the power of our data Deepen customer connections & Evolving market and margin pressure extend reach continue to be a driver • 340B data now transitioned onto Trisus, providing the opportunity to • Our solutions ability to mitigate the • A
Slide 20: Strong foundations to deliver growth from FY28
Conclusion & Outlook Strong foundations to deliver growth from FY28 Hospitals need to Reimbursement We have Best in Innovating at Financial reset protect operating complexity and KLAS® offerings pace, combining provides certainty margins, without regulatory which are deeply our data sets, AI and opp
Slide 21: Questions?
Questions? © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 21
Slide 22: Appendix
Appendix © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 22
Slide 23: General Information
Major shareholders % of Issued Shareholder Share Capital Keith Neilson (CEO & co-founder) 9.42% General Information Octopus Investments 7.19% Liontrust Asset Management 6.70% • Share Price 1300p (at 17/09/2026) Gordon Craig (co-founder) 6.06% • Market AIM • Ticker CRW Richard Griffiths 4.28% • Marke
Slide 24: The Craneware Group Key Strengths
The Craneware Group Key Strengths Significant Strong Extensive Attractive SaaS Positive Impact Market Need Competitive Position Customer Base Business Model On Society Healthcare Providers face: Our independence means: Our solutions deliver: Our customers enjoy: Our Customers report: • Regulatory ch
Slide 25: Evolving 340B market and our approach
Market Update: Spotlight on 340B Evolving 340B market and our approach (Video) The 340B Market in Transition Engineering for What Comes Next • 340B is maturing. • The challenge is expanding beyond • 340B is becoming an enterprise financial traditional 340B workflows. issue. • Trisus OneLink – Medica
Slide 26: Forward Looking Statements
Forward Looking Statements This Report may contain forward-looking statements. Any forward-looking statement has been made by the directors in good faith based on the information available to them up to the time of approval of this Statement and should be treated with caution due to the inherent unc